Date: 2015-08-06
Type of information: R&D agreement
Compound: HuMab 5B1
Company: MabVax Therapeutics (USA - CA) The Rockefeller University (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: monoclonal antibody
Disease:
Details: * On August 6, 2015, MabVax Therapeutics, a clinical stage oncology drug development company, and The Rockefeller University\'s Laboratory of Molecular Genetics and Immunology have entered into a research collaboration agreement to explore the mechanism of action of constant region (Fc) variants of the HuMab 5B1 in the role of tumor clearance. The objective is to optimize Fc receptor mediated antibody function. The work will be conducted in the Laboratory of Molecular Genetics and Immunology at The Rockefeller University, which is headed by Jeffery Ravetch, M.D., Ph.D. Dr. Ravetch is a leading researcher who unraveled the importance of the antibody constant region (Fc) and described the mechanisms of antibody-mediated effector responses. The Fc portion of an antibody plays a critical functional role by binding to various cellular receptors as well as complement proteins, and it is responsible for recruiting other immune system cells to attack the tumor cell resulting in destruction of the targeted cell. The Company recently announced that it will file investigational new drug (IND) applications with the FDA for a HuMab 5B1-based therapeutic product and a next generation PET imaging agent later this year. The Company anticipates initiating Phase I trials in the first quarter of 2016.
Financial terms:
Latest news:
